Memantine is a N-methyl-D-aspartate receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. It is available as tablets, extended-release capsules and oral solution. MedsAcross supplies Memantine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Memantine hydrochloride tablets are an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type.
Source: US FDA prescribing information
Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer’s disease.
Source: US FDA prescribing information
The recommended starting dose of memantine hydrochloride tablets is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day. Memantine hydrochloride tablets can be taken with or without food. If a patient misses a single dose of memantine hydrochloride, that patient should not double up on the next dose. The next dose should be taken as scheduled. If a patient fails to take memantine hydrochloride tablets for several days, dosing may need to be resumed at lower doses and retitrated as described above.
Source: US FDA prescribing information
Memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.
Source: US FDA prescribing information
Conditions that raise urine pH may decrease the urinary elimination of memantine, resulting in increased plasma levels of memantine. Genitourinary Conditions Conditions that raise urine pH may decrease the urinary elimination of memantine resulting in increased plasma levels of memantine.
Source: US FDA prescribing information
Most common adverse reactions (≥ 5 % and greater than placebo) are dizziness, headache, confusion and constipation.
Source: US FDA prescribing information
7. 1 Drugs that Make t he Urine Alkaline The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions.
Source: US FDA prescribing information
Store memantine hydrochloride tablets at 25°C (77°F), excursions permitted to 15-30°C (59-86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
8 presentations of Memantine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Memantine 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Memantine 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Memantine 28 mg extended-release capsuleOralGeneric name | — | US FDA | Available on request |
| Memantine 14 mg extended-release capsuleOralGeneric name | — | US FDA | Available on request |
| Memantine 7 mg extended-release capsuleOralGeneric name | — | US FDA | Available on request |
| Memantine 21 mg extended-release capsuleOralGeneric name | — | US FDA | Available on request |
| Memantine 2 mg/mL oral solutionOralGeneric name | — | US FDA | Available on request |
| Memantine kitOralGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Memantine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 8 presentations of Memantine and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Memantine on 16 October 2003, according to Drugs@FDA.
Yes. Memantine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Memantine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Memantine is classified under ATC code N06DX01 (Memantine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.